Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [4] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [4] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and employs a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [4] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, and it shows potential synergy with checkpoint inhibitors [4] Upcoming Events - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - Management will also be available for in-person one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 5, 2025, and will be archived for 90 days [3]